Interstitial cystitis: An update

Current Opinion in Urology

Volumn 12, Issue 4, 2002, Pages 321-332

  Oberpenning, Frank ^a   Van Ophoven, Arndt ^a   Hertle, Lothar ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Interstitial cystitis; Pelvic pain syndrome; Urethral syndrome

Indexed keywords

ARGININE; BCG VACCINE; BIOFLAVONOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DIMETHYL SULFOXIDE; FLAVONOID; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MONTELUKAST; OXYBUTYNIN; PENTOSAN POLYSULFATE; QUERCETIN; RESINIFERATOXIN; SUPLATAST TOSYLATE; TOLTERODINE;

BLADDER; BLADDER BIOPSY; BLADDER PERMEABILITY; CLINICAL FEATURE; CLINICAL TRIAL; CYSTOSCOPY; DIAGNOSTIC TEST; GASTROINTESTINAL TOXICITY; GENETIC SUSCEPTIBILITY; HOLMIUM LASER; HUMAN; INTERSTITIAL CYSTITIS; MAST CELL; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; UROTHELIUM; VALIDATION PROCESS;

ANIMALS; CYSTITIS, INTERSTITIAL; DISEASE MODELS, ANIMAL; HUMANS; QUALITY OF LIFE; URODYNAMICS;

EID: 0036288278     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200207000-00011     Document Type: Review

References (134)

1. Interstitial cystitis: Current issues and controversies in diagnosis
2. Chronic urologic pain syndromes
3. Information from your family doctor. Interstitial cystitis: A bladder problem
4. Interstitial cystitis: Urgency and frequency syndrome
5. Interstitial cystitis from the angle of evidence-based medicine
6. Interstitial cystitis: A chronic inflammatory bladder condition
7. Interstitial cystitis
8. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association Scientific Conference on Interstitial Cystitis
9. Current controversies that adversely affect interstitial cystitis patients
10. Interstitial cystitis: Past and future
11. Interstitial cystitis: A time for revision of name and diagnostic criteria in the new millennium?
12. Review on chronic pelvic pain from a urological point of view
13. New agents for the medical treatment of interstitial cystitis
14. Chronic interstitial cystitis
15. Clinical characteristics support that interstitial cystitis is a heterogeneous syndrome
16. Immunologic and neurobiologic characteristics support that interstitial cystitis is a heterogeneous syndrome
17. Diagnosing interstitial cystitis in women with chronic pelvic pain
18. Gynecologic presentation of interstitial cystitis as detected by intravesical potassium sensitivity
19. Understanding chronic pelvic pain syndrome
20. Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis
21. Dynamic interactions between host and pathogen during acute urinary tract infections
22. Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome
23. The incidence of Chlamydia trachomatis in women with urethral syndrome
24. A study to detect Gardnerella vaginalis DNA in interstitial cystitis
25. Mast cell involvement in interstitial cystitis: A review of human and experimental evidence
26. Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice
27. Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma
28. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis
29. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor
30. Chlorpactin instillation releases calcitonin gene-related peptide in interstitial cystitis patients
31. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis
32. Urinary levels of substance P and its metabolites are not increased in interstitial cystitis
33. Urinary substance P concentration correlates with urinary frequency and urgency in interstitial cystitis patients treated with intravesical dimethyl sulfoxide and not intravesical anesthetic cocktail
34. Estrogen and neuroinflammation
35. Estrous influences on micturition thresholds of the female rat before and after bladder inflammation
36. Diurnal cortisol variations and symptoms in patients with interstitial cystitis
37. Increased plasma norepinephrine concentration in cats with interstitial cystitis
38. Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder
39. The epidemiology of interstitial cystitis: Is it time to expand our definition?
40. A case of familial clustering of interstitial cystitis and chronic pelvic pain syndrome
41. Fishbein/Interstitial Cystitis Association (ICA) survey of interstitial cystitis among family members of ICA members: Preliminary analysis
42. Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs
43. Basic science research on the urinary bladder and interstitial cystitis: New genetic approaches
44. The psychosocial economic impact of invisible chronic disease: Examining the experience of patients with interstitial cystitis
45. Nonbladder related symptoms in patients with interstitial cystitis
46. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29; 1987
47. The diagnosis of interstitial cystitis revisited: Lessons learned from the National Institutes of Health Interstitial Cystitis Database study
48. Interstitial cystitis: Reevaluation of patients who do not respond to standard treatments
49. How do patients with interstitial cystitis present?
50. The interstitial cystitis symptom index and problem index
51. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium
52. Correlation of symptoms between 2 instruments among interstitial cystitis patients
53. Significance of hematuria in patients with interstitial cystitis: Review of radiographic and endoscopic findings
54. Bladder microvasculature and the effects of hydrodistention in interstitial cystitis
55. To study the effect of hydrodistension on bladder mucosa and submucosa
56. Lidocaine cystometry in the diagnosis of bladder overactivity
57. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation
58. Biopsy features are associated with primary symptoms in interstitial cystitis: Results from the interstitial cystitis database study
59. The comparison of clinical and histopathologic features of interstitial cystitis
60. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis
61. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis
62. The intravesical potassium sensitivity test and urodynamics: Implications in a large cohort of patients with lower urinary tract symptoms
63. An assessment of the use of intravesical potassium in the diagnosis of interstitial cystitis
64. Effect of physiologic levels of urinary potassium on interstitial cystitis symptoms
65. Re: A new direct test of bladder permeability
66. A new direct test of bladder permeability
67. Intravesical ethanol as quantitative measure of bladder hyperpermeability
68. A diagnostic in vitro urine assay for interstitial cystitis
69. Decreased 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients
70. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients
71. Concentrations of specific epithetial growth factors in the urine of interstitial cystitis patients and controls
72. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis
73. Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis
74. Urine markers of interstitial cystitis
75. Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume
76. Morphological examination of the effects of defibrotide on experimentally induced bladder injury and its relation to interstitial cystitis
77. In vivo models of interstitial cystitis
78. A reliable, nondestructive animal model for interstitial cystitis: Intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride
79. Interstitial cystitis in India: Important lessons
80. Interstitial cystitis in males
81. Observations on the presentation, diagnosis, and treatment of interstitial cystitis in men
82. Interstitial cystitis in children
83. Epidemiology of interstitial cystitis
84. Interstitial cystitis in children: Not a rare entity
85. Is interstitial cystitis an underdiagnosed problem in children? A diagnostic and therapeutic dilemma
86. Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis
87. Medical therapy in interstitial cystitis: The Essex experience
88. Oral cimetidine gives effective symptom relief in painful bladder disease: A prospective, randomized, double-blind placebo-controlled trial
89. Cimetidine in painful bladder syndrome: A histopathological study
90. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine
91. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis
92. Tolterodine: A safe and effective treatment for older patients with overactive bladder
93. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial
94. Oral therapies for interstitial cystitis
95. Interstitial cystitis and the potential role of gabapentin
96. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain
97. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T
98. Quercetin in men with category III chronic prostatitis: A preliminary prospective, double-blind, placebo-controlled trial
99. Treatment of interstitial cystitis with a quercetin supplement
100. Recombinant human nerve growth factor in the treatment of interstitial cystitis: Preliminary results
101. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis
102. Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: A simple method for improving bladder anesthesia
103. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis
104. The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: A double-blind, prospective, placebo controlled trial
105. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: Long-term follow-up
106. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: A prospective, randomized double-blind study
107. Lens deposits associated with RIMSO-50 (dimethylsulphoxide)
108. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis
109. Cystistat for the treatment of interstitial cystitis: A 3-year follow-up study
110. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress
111. RTX exotoxins
112. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlled study
113. A light- and electron-microscopic histopathological study of human bladder mucosa after intravesical resiniferatoxin application
114. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: Efficacy at 6 months and 1 year
115. Use of the neodymium:YAG laser for interstitial cystitis: A prospective study
116. Lumbar sympathetic block for pain relief in two patients with interstitial cystitis
117. Sacral neurostimulation and neuromodulation in urological practice
118. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: Results from a national register
119. First Scandinavian experience of electrical sacral nerve stimulation in the treatment of the overactive bladder
120. Sacral nerve neuromodulation in the treatment of refractory motor urge incontinence
121. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence
122. Sacral nerve stimulation in patients with chronic, intractable pelvic pain
123. Re: Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis
124. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis
125. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis
126. Stress and symptoms in patients with interstitial cystitis: A life stress model
127. A laboratory stress model for examining stress and symptomatology in interstitial cystitis patients
128. Symptom reports among interstitial cystitis patients
129. Pelvic floor myofascial trigger points: Manual therapy for interstitial cystitis and the urgency-frequency syndrome
130. The effect of manual physical therapy in patients diagnosed with interstitial cystitis, high-tone pelvic floor dysfunction, and sacroiliac dysfunction
131. Evaluation of transvaginal theile massage as a therapeutic intervention for women with interstitial cystitis
132. The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis
133. Practice trends for the management of interstitial cystitis
134. Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis